Filip Fredlund, PhD, is Head of In Vivo at Redoxis, where he leads the company’s in vivo operations and supports the continued development of high-quality preclinical research services. He combines scientific expertise with a collaborative leadership approach, ensuring efficient study execution and close alignment with customer needs.
Filip holds a PhD in Neuroimmunology and has a research background focused on neuroinflammatory disease mechanisms and experimental models of central nervous system inflammation. His scientific expertise spans both in vivo and in vitro approaches to investigating disease mechanisms and evaluating novel therapeutic interventions.
In addition to leading the in vivo team, Filip works closely with project leaders and scientists to ensure robust study design, operational excellence, and the generation of reliable, decision-enabling preclinical data. His expertise in neuroimmunology and inflammation strengthens Redoxis’ capabilities across immune-mediated and autoimmune diseases.
